## **Supporting Information (S3 Fig)**

	Tolvaptan			Control			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Gheorghiade 2003	2.66	3.23	187	0	5.2	62	12.1%	2.66 [1.29, 4.03]	
Gheorghiade 2004 [ACTIV]	3.22	4	239	-0.2	3.12	80	14.1%	3.42 [2.57, 4.27]	
Gheorghiade 2007	3.28	4.11	1743	-0.41	3.53	1772	15.6%	3.69 [3.44, 3.94]	<del>-</del>
Jujo 2016	4.07	6.05	30	1.13	4.72	30	7.1%	2.94 [0.19, 5.69]	•
Matsue 2016	1.16	1.76	108	-0.06	1.56	109	15.3%	1.22 [0.78, 1.66]	<del></del>
3hanmugam 2016	2.75	5.21	25	1.15	3.29	26	8.1%	1.60 [-0.80, 4.00]	-
Jdelson 2008 [ECLIPSE]	3.05	4.13	133	-0.7	3.2	48	13.0%	3.75 [2.60, 4.90]	
Udelson 2011	2.04	1.12	20	-0.15	1.07	21	14.7%	2.19 [1.52, 2.86]	
Total (95% CI)			2485			2148	100.0%	2.71 [1.73, 3.70]	•
Heterogeneity: Tau² = 1.60; Chi² = 100.25, df = 7 (P < 0.00001); I² = 93%								-4 -2 0 2 4	
Test for overall effect: Z = 5.41 (P < 0.00001)								Favours Control Favours Tolvaptan	

S3 Fig. Forest plot of direct comparison: Tolvaptan versus Control. Efficacy outcome: change of serum sodium at 24-hr